SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed by a party other than the Registrant ☐
Check the appropriate box:
|☐||Preliminary Proxy Statement|
|☐||Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))|
|☐||Definitive Proxy Statement|
|☒||Definitive Additional Materials|
|☐||Soliciting Material Pursuant to §240.14a-12|
AVEO PHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)
Payment of Filing Fee (Check the appropriate box):
|☒||No fee required.|
|☐||Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.|
|(1)||Title of each class of securities to which transaction applies:|
|(2)||Aggregate number of securities to which transaction applies:|
|(3)||Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):|
|(4)||Proposed maximum aggregate value of transaction:|
|(5)||Total fee paid:|
|☐||Fee paid previously with preliminary materials:|
|☐||Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.|
|(1)||Amount Previously Paid:|
|(2)||Form, Schedule or Registration Statement No.:|
|☐||Preliminary Proxy Statement|
ONE BROADWAY, 14TH FLOOR CAMBRIDGE, MASSACHUSETTS 02142
SUPPLEMENT TO THE PROXY STATEMENT FOR
THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 21, 2017
May 17, 2017
This Supplement relates to the proxy statement, dated April 27, 2017 (the 2017 Proxy Statement), of AVEO Pharmaceuticals, Inc. (the Company) for its 2017 Annual Meeting of Stockholders to be held at One Broadway, 5th Floor, Cambridge, MA 02142 on Wednesday, June 21, 2017 at 10:00 a.m., Eastern Daylight Time.
This supplemental information should be read in conjunction with the 2017 Proxy Statement, which should be read in its entirety.
In light of the untimely passing of Mr. Henri A. Termeer, a member of the Companys Board of Directors (Board), on May 12, 2017, the Board has reduced the size of the Board from five to four members. The Board is not nominating a replacement Director at this time, but will initiate a process to potentially add one or more directors to the Board in the future. The Company has named Kenneth M. Bate as Lead Director. The Board also recomposed the members of the standing committees of the Board as follows:
Audit Committee: Kenneth M. Bate (chair), Anthony B. Evnin, Ph.D. and Robert C. Young, M.D.;
Compensation Committee: Kenneth M. Bate, Anthony B. Evnin, Ph.D. (chair) and Robert C. Young, M.D.;
Nominating and Governance Committee: Anthony B. Evnin, Ph.D. and Robert C. Young, M.D. (chair).
The other four nominees named in the 2017 Proxy Statement, Messrs. Bailey and Bate and Drs. Evnin and Young, will continue to stand for election at the 2017 Annual Meeting of Stockholders. The form of proxy card included in the original distribution of the 2017 Proxy Statement remains valid; however, any votes that are submitted with instructions to vote for all of the Boards nominees will be voted only for the four remaining nominees, as named in the 2017 Proxy Statement.